Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (NQ: INM )

0.2735 -0.0048 (-1.72%)
Streaming Delayed Price Updated: 2:43 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inmed Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor
Via Investor Brand Network
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller
Via Investor Brand Network
InMed Provides Update on Management Changes
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
InMed Pharmaceuticals (NASDAQ: INM) Says Research Grant to Test Cannabinoid Analogs as a Potential Treatment for Alzheimer’s, Parkinson’s and Huntington’s Disease
InMed Pharmaceuticals, Inc. (NASDAQ: INM) is a pharmaceutical research and development company that is focused on utilizing cannabinoids and related 
Via Spotlight Growth
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor
Via Investor Brand Network
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update
Via Investor Brand Network
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event
Via Investor Brand Network
Registration Now Open For Tribe Public’s Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMed’s Management Team On November 17, 2022
Meet with InMed’s President and CEO Eric A. Adams and Eric Hsu, SVP of Preclinical Research and Development 
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Support of EB Awareness Week
Via Investor Brand Network
InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces 2022 Financial Results, Business Update
Via CannabisNewsWire
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update
Via Investor Brand Network
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $6M Private Placement Agreement
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters into $6M Securities Purchase Agreement
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Shares Record Huge Gains in Monday Morning Trading
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Update on Company Objectives and Programs
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial
Via Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.